+ Hemp-Derived Delta-9, Amazon’s Hemp Problem, DEA’s Roadblock, & More!
Most Popular This Month | Where Will Hemp-Derived Delta-9 THC Products Land in 2025 (and Beyond)? | The future of hemp-derived delta-8 and -9 THC products remains unclear leading up to this year’s anticipated reauthorization of the 2018 Farm Bill, as a patchwork of state regulations have gone unaddressed at the federal level.
But as products containing these intoxicating hemp derivatives have taken off in consumer popularity and business profitability in recent years, the fate of this marketplace continues to attract the attention of regulators, stakeholders and our readers at Cannabis Business Times.
Leading our monthly list of top 10 articles in March was a contributed piece by a quartet of attorneys at Goodwin Procter LLP, who provided a thorough examination of the widespread availability for hemp-derived delta-9 products, federal and state regulations, and what could be next for U.S. hemp cultivators and processors counting on this cannabinoid.
On a similar topic, an article by CBT Editorial Director Noelle Skodzinski about hemp-related products sold on Amazon that violate federal regulations, according to a report by CBD Oracle, took the No. 2 spot in this month’s most-read articles.
Among other articles readers engaged with most included those on a potential cannabis rescheduling roadblock with the U.S. Drug Enforcement Administration’s five-factor test; federal lawmakers challenging forthcoming tribal cannabis sales in North Carolina; and Trulieve’s $113 million refund for 280E taxes paid. Catch Up on All The Top 10 Stories From March | No. 10: Behind the Curtains | VP Harris: ‘We Need to Legalize Marijuana’ | NORML Regional Coordinator Chris Goldstein takes us inside the closed-door White House roundtable discussion on criminal justice and cannabis drug policy and shares why he feels this is ‘the beginning of the end of the drug war.’ More >>> | No. 9: Up, Up and Away! | How Big Is the U.S. Market for Delta-8 THC and Other Hemp-Derived Cannabinoids? | Data from Brightfield Group shows the market may be bigger and growing faster than you might think. More >>> | No. 8: An Outdated Structure | Will Canada’s Cannabis Excise Tax Be Lowered? | Canada’s Standing Committee on Finance recommended reducing the tax and adjusting excise stamp requirements. What would this mean and why is one expert moderating expectations? More >>> | No. 7: Florida's Big Decision | Is Gov. DeSantis Providing Smoke Signals to Supreme Court on Florida’s Cannabis Measure? | Saul Ewing cannabis attorney Zachary Kobrin says the governor’s recent string of comments has the rumor mill churning. More >>> | No. 6: New Waves in the Industry | Trulieve Reports Receiving Refund For 280E Taxes Paid | The multistate cannabis company, as noted in its 2023 financial report and earnings call, says it received $113 million of the more than $174 million it requested in combined amended state and federal tax returns. More >>> | No. 5: All or Nothing | 'Deschedule or Do Nothing:' Drug Policy Alliance Says Rescheduling Cannabis Would Not End Criminalization | Drug Policy Alliance and representatives from other cannabis organizations and businesses explained the limitations and potential harms of relisting cannabis as a Schedule III drug from Schedule I of the Controlled Substances Act in a special virtual press briefing. More >>> | No. 4: Testing Tribal Sovereignty | 2 US Senators Urge DEA, Other Agencies to ‘Uphold’ Law on Tribal Cannabis Sales in North Carolina | The Eastern Band of Cherokee Indians plans to launch the state’s first adult-use cannabis sales on April 20. More >>> | No. 3: Rescheduling Roadblock? | DEA’s 5-Factor Test Makes Rescheduling Cannabis Impossible | After HHS used its own two-part test to determine the plant’s ‘currently accepted medical use,’ rescheduling opponents urge DEA to keep its five-part test. More >>> | No. 2: An Independent Analysis | Amazon’s CBD, Hemp and Delta-8 Problem | A new study of hemp products sold on Amazon found that nearly half contained no hemp, several contained high doses of delta-8 THC, and more than half made an unapproved medical claim, among other concerns. More >>> | No. 1: All Eyes on Farm Bill Reauthorization | Hemp-Derived Delta-9 THC: What’s Next? | A patchwork of state regulations for hemp-derived delta-9 THC products is emerging. Here’s the rundown and what the future may hold for this chemically converted cannabinoid. More >>> |
About CBT: Cannabis Business Times is the most trusted source of actionable intelligence for plant-touching cannabis businesses throughout North America. | |